Population pharmacokinetics of recombinant factor VIII Fc fusion protein

Clinical Pharmacology in Drug Development

Volumn 4, Issue 3, 2015, Pages 163-174

  Nestorov, Ivan ^a   Neelakantan, Srividya ^a   Ludden, Thomas M ^b   Li, Shuanglian ^a   Jiang, Haiyan ^a   Rogge, Mark ^a  

^a BIOGEN   (United States)

^b Consultant ^*  (United States)

Author keywords

Dosing regimen; Hemophilia A; Modeling; Population pharmacokinetics; Recombinant factor VIII Fc fusion protein

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT FACTOR VIII IMMUNOGLOBULIN FC FRAGMENT FUSION PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; BLOOD CLOTTING FACTOR 8; FACTOR VIII-FC FUSION PROTEIN; HEMOSTATIC AGENT; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT;

ARTICLE; BODY WEIGHT; COMPARTMENT MODEL; DOSE RESPONSE; DRUG CLEARANCE; HEMATOCRIT; HEMOPHILIA A; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; SINGLE DRUG DOSE; STEADY STATE; VOLUME OF DISTRIBUTION; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; COMPUTER SIMULATION; CROSSOVER PROCEDURE; DRUG EFFECTS; HEMOSTASIS; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLIC CLEARANCE RATE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

BODY WEIGHT; COMPUTER SIMULATION; CROSS-OVER STUDIES; FACTOR VIII; HEMATOCRIT; HEMOPHILIA A; HEMOSTASIS; HEMOSTATICS; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; RECOMBINANT FUSION PROTEINS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84929607738     PISSN: 2160763X     EISSN: 21607648     Source Type: Journal    
DOI: 10.1002/cpdd.167     Document Type: Article

References (33)

1. Mannucci PM, Tuddenham EG. The hemophilias-from royal genes to gene therapy. N Engl J Med. 2001; 344:1773-1779.
2. Dragani A, Malizia R, Iuliani O, Di M I, Davi G. Inherited bleeding disorders: results from the Italian Regional Haemophilia Centre of Pescara. Blood Transfus. 2008; 6:136-142.
3. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013; 19:e1-e47.
4. Fernandez-Lopez O, Garcia-Lozano JR, Nunez-Vazquez R, Perez-Garrido R, Nunez-Roldan A. The spectrum of mutations in Southern Spanish patients with hemophilia A and identification of 28 novel mutations. Haematologica. 2005; 90:707-710.
5. David D, Ventura C, Moreira I, et al. The spectrum of mutations and molecular pathogenesis of hemophilia A in 181 Portuguese patients. Haematologica. 2006; 91:840-843.
6. Green PM, Bagnall RD, Waseem NH, Giannelli F. Haemophilia A mutations in the UK: results of screening one-third of the population. Br J Haematol. 2008; 143:115-128.
7. Margaglione M, Castaman G, Morfini M, et al. The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype. Haematologica. 2008; 93:722-728.
8. Carcao MD, Van Den Berg HM, Ljung R, Mancuso ME. Correlation between phenotype and genotype in a large unselected cohort of children with severe hemophilia A. Blood. 2013; 121:3946-3952, S1.
9. Tusell JM, Aznar JA, Querol F, Quintana M, Moreno M, Gorina E. Results of an orthopaedic survey in young patients with severe haemophilia in Spain. Haemophilia. 2002; 8(Suppl 2):38-42.
10. Soucie JM, Cianfrini C, Janco RL, et al. Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. Blood. 2004; 103:2467-2473.
11. van Genderen FR, Fischer K, Heijnen L, et al. Pain and functional limitations in patients with severe haemophilia. Haemophilia. 2006; 12:147-153.
12. Hegeman AK, van Genderen FR, Meijer S, Van Den Briel MM, Tamminga RY, Van WE. Perceived competence in children and adolescents with haemophilia: an explorative study. Haemophilia. 2011; 17:81-89.
13. Plug I, Peters M, Mauser-Bunschoten EP, et al. Social participation of patients with hemophilia in the Netherlands. Blood. 2008; 111:1811-1815.
14. Escobar MA. Health economics in haemophilia: a review from the clinician's perspective. Haemophilia. 2010; 16(Suppl 3):29-34.
15. Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost. 2011; 9:700-710.
16. Noone D, O'Mahony B, van Dijk JP, Prihodova L. A survey of the outcome of prophylaxis, on-demand treatment or combined treatment in 18-35-year old men with severe haemophilia in six countries. Haemophilia. 2013; 19:44-50.
17. MASAC. Recommendation #190 Concerning Products Licensed for the Treatment of Hemophilia and Other Bleeding Disorders. March 2009 (Replaced by Recommendation #215, November 2012). New York, NY: National Hemophilia Foundation; 2012.
18. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet. 2003; 361:1801-1809.
19. Hermans C, Altisent C, Batorova A, et al. Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations. Haemophilia. 2009; 15:639-658.
20. Collins PW, Blanchette VS, Fischer K, et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost. 2009; 7:413-420.
21. Powell JS, Josephson NC, Quon D, et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood. 2012; 119:3031-3037.
22. Mahlangu J, Powell JS, Ragni MV, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014; 123:317-325.
23. Bjorkman S, Folkesson A, Jonsson S. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. Eur J Clin Pharmacol. 2009; 65:989-998.
24. Karafoulidou A, Suarez E, Anastasopoulou I, et al. Population pharmacokinetics of recombinant factor VIII:C (ReFacto) in adult HIV-negative and HIV-positive haemophilia patients. Eur J Clin Pharmacol. 2009; 65:1121-1130.
25. Bjorkman S, Blanchette VS, Fischer K, et al. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. J Thromb Haemost. 2010; 8:730-736.
26. Bjorkman S, Oh M, Spotts G, et al. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood. 2012; 119:612-618.
27. Bjorkman S, Ahlen V. Population pharmacokinetics of plasma-derived factor IX in adult patients with haemophilia B: implications for dosing in prophylaxis. Eur J Clin Pharmacol. 2012; 68:969-977.
28. Bjorkman S, Carlsson M, Berntorp E. Pharmacokinetics of factor IX in patients with haemophilia B. Methodological aspects and physiological interpretation. Eur J Clin Pharmacol. 1994; 46:325-332.
29. Carlsson M, Bjorkman S, Berntorp E. Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis. Haemophilia. 1998; 4:83-88.
30. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001; 28:481-504.
31. Ahn JE, Karlsson MO, Dunne A, Ludden TM. Erratum to: likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn. 2010; 37:305-308.
32. Bjorkman S. Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A. Haemophilia. 2010; 16:597-605.
33. Bjorkman S. Evaluation of the TCIWorks Bayesian computer program for estimation of individual pharmacokinetics of FVIII. Haemophilia. 2011; 17:e239-e240.